Similar articles

• Tumour deposit count is an independent prognostic factor in colorectal cancer-a population-based cohort study.

  Lundström S, Agger E, Lydrup ML, Jörgren F, Buchwald P. Lundström S, et al. Br J Surg. 2024 Dec 24;112(1):znae309. doi: 10.1093/bjs/znae309. Br J Surg. 2024. PMID: 39787029 Free PMC article.
• Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer.

  Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G, Platell C. Cirocchi R, et al. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD008997. doi: 10.1002/14651858.CD008997.pub2. Cochrane Database Syst Rev. 2012. PMID: 22895981 Free PMC article.
• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

  Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R. Bryant A, et al. Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
• Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

  Tappenden P, Jones R, Paisley S, Carroll C. Tappenden P, et al. Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. doi: 10.3310/hta11120. Health Technol Assess. 2007. PMID: 17346499
• Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

  Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M. Williams C, et al. Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170